重度忧郁症（MDD）：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

市场概览

• 德国 MDD 市场预计将从 2025 年的约 2.4 亿美元成长到 2035 年的约 5.65 亿美元，复合年增长率约为 8-9%。
• 义大利确诊病例数仅略有成长（年均复合成长率约0.4%），显示：
• 该疾病的盛行率保持稳定。
• 市场成长更多是由治疗创新驱动，而不是由患者数量的增加所驱动。

重度忧郁症（MDD）概述

重度忧郁症（MDD）是一种常见且严重的精神障碍，其特征是持续性情绪低落、快感缺失（兴趣或愉悦感丧失）以及功能障碍，且持续至少两週。它影响所有年龄层的人群，是由遗传、神经生物学、心理学和环境因素之间复杂的相互作用引起的。

临床上，重度忧郁症表现为多种症状，包括疲劳、睡眠障碍、食慾改变、注意力难以集中、内疚和无价值感，严重时可能伴随自杀意念或自杀行为。

此疾病的诊断主要依据临床表现，并参考DSM-5等标准化诊断标准，在仔细排除其他精神和生理疾病后进行。此疾病具有高度异质性，其严重程度、復发率和治疗反应均有差异。

治疗涉及多方面因素，包括以下内容：

• 心理治疗（主要是认知行为治疗）
• 药物治疗（SSRIs、SNRIs 和其他抗忧郁症）
• 生活方式改善和支持性干预

儘管存在多种治疗选择，但相当一部分患者表现出治疗抗药性或仅获得不完全疗效，这凸显出仍存在大量未满足的需求。

主要亮点

• 法国被诊断出患有重度忧郁症(MDD) 的人数众多且相对稳定，预计将从 2025 年的约 443 万人增加到 2035 年的约 459 万人，但这反映出成长率较低（年复合成长率约为 0.4%）。
• 相当一部分患者（约 20-30%）被归类为患有难治性忧郁症(TRD)，这推动了对先进疗法的需求。
• 目前的治疗领域仍以学名药主导。
• SSRI 和 SNRI 被用作第一线治疗药物（约占 60-70% 的市场份额）。
• 辅助性治疗（抗精神病药物、情绪稳定剂）的广泛应用

格式化和更新讯息

• 详细报告（PDF）
• 市场预测模型（基于微软Excel）
• 流行病学数据（MS Excel，互动式工具）
• 高阶主管洞察（PPT简报）
• 其他功能：定期更新、自订和顾问支援。
• 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

• 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
• 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
• 未来十年市场收入和病患份额的预测是多少？
• 哪些因素对市场趋势影响最大？
• 受访专家对目前和新兴疗法有何看法？
• 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
• 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
• 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

• G8
  • 我们
  • EU5
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
  • 日本
  • 中国

大公司

• Biohaven Therapeutics Ltd.
• Cybin IRL Limited
• Xenon Pharmaceuticals Inc.
• Neurocrine Biosciences
• Biogen
• Eli Lilly and Company
• AbbVie
• Axsome Therapeutics, Inc.
• Otsuka Pharmaceutical Development &Commercialization, Inc.
• Neumora Therapeutics, Inc.
• Engrail Therapeutics INC
• Janssen-Cilag Ltd.
• Autobahn Therapeutics, Inc.
• Navitor Pharmaceuticals, Inc.
• Takeda
• Syndeio Biosciences, Inc
• Suven Life Sciences Limited
• Definium Therapeutics US, Inc.
• Boehringer Ingelheim
• Relmada Therapeutics, Inc.
• Sirtsei Pharmaceuticals, Inc.
• Intra-Cellular Therapies, Inc.
• COMPASS Pathways
• Beijing Greatway Pharmaceutical Technology Co.,Ltd.
• Bausch Health Americas, Inc.
• Alto Neuroscience
• Gilgamesh Pharmaceuticals
• BioLite, Inc.
• Luye Pharma Group Ltd.
• Vigonvita Life Sciences
• Draig Therapeutics Ltd
• Supernus Pharmaceuticals, Inc.
• Ono Pharmaceutical Co. Ltd
• CSPC Ouyi Pharmaceutical Co., Ltd.
• Zhejiang Huahai Pharmaceutical Co., Ltd.
• Chengdu Kanghong Pharmaceutical Group Co., Ltd.
• Vanda Pharmaceuticals
• Seaport Therapeutics
• Jiangsu Nhwa Pharmaceutical Co., Ltd.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Sichuan Purity Pharmaceutical Technology Co., Ltd.
• ACADIA Pharmaceuticals Inc.
• Corium Innovations, Inc.

目录

第一章：主要调查结果及分析师说明

• 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

• 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

• 重点
• 发病率/盛行率
• 已确诊并接受药物治疗的患者人数
• 合併症
• 其他相关患者群

第四章 市场规模及预测

• 重点
• 市场驱动因素与限制因素
• 按药物类别分類的趋势
• 各国具体趋势

第五章 竞争情势

• 目前疗法
  • 重点
  • 诊断和治疗过程/演算法
  • 主要疗法概述及KOL洞察
• 新兴疗法
  • 重点
  • 值得关注的后期新疗法—概述、市场上市预期和KOL洞察
  • 值得关注的早期研发管线

第六章：未满足的需求与目标产品分析

• 主要未满足的需求以及透过新兴疗法实现的未来可能性
• TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

Major Depressive Disorder (MDD) Market Outlook

Thelansis's "Major Depressive Disorder (MDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Major Depressive Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Major Depressive Disorder (MDD) Overview

Major Depressive Disorder (MDD) is a common and serious psychiatric condition characterized by persistent low mood, anhedonia (loss of interest or pleasure), and functional impairment lasting at least two weeks. It affects individuals across all age groups and is driven by a complex interplay of genetic, neurobiological, psychological, and environmental factors.

Clinically, MDD presents with a broad spectrum of symptoms, including fatigue, sleep disturbances, appetite changes, impaired concentration, and feelings of guilt or worthlessness, with severe cases associated with suicidal ideation or behavior.

Diagnosis is clinical and based on standardized criteria such as DSM-5, with careful exclusion of other psychiatric or medical conditions. The disorder is highly heterogeneous, with variability in severity, recurrence, and treatment response.

Management is multimodal and includes:

• Psychotherapy (primarily cognitive behavioral therapy)
• Pharmacotherapy (SSRIs, SNRIs, and other antidepressants)
• Lifestyle and supportive interventions

Despite the availability of multiple treatment options, a significant proportion of patients experience treatment resistance or incomplete response, highlighting substantial unmet need.

Key Highlights

• The diagnosed MDD population in France is large and relatively stable, increasing from ~4.43 million in 2025 to ~4.59 million by 2035, reflecting a low growth rate (~0.4% CAGR).
• A considerable proportion of patients fall into the treatment-resistant depression (TRD) category (~20-30%), driving demand for advanced therapies.
• The treatment landscape remains highly generic-driven, with:
• SSRIs and SNRIs as first-line therapies (~60-70% share)
• Widespread use of adjunct therapies (antipsychotics, mood stabilizers)

Market Overview

• The MDD market in Germany is projected to grow from ~$240M in 2025 to ~$565M by 2035, reflecting a strong CAGR of ~8-9%.
• The diagnosed population in Italy shows minimal growth (~0.4% CAGR), indicating:
• Stable disease prevalence
• Market growth driven more by treatment innovation than patient expansion

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Biohaven Therapeutics Ltd.
• Cybin IRL Limited
• Xenon Pharmaceuticals Inc.
• Neurocrine Biosciences
• Biogen
• Eli Lilly and Company
• AbbVie
• Axsome Therapeutics, Inc.
• Otsuka Pharmaceutical Development & Commercialization, Inc.
• Neumora Therapeutics, Inc.
• Engrail Therapeutics INC
• Janssen-Cilag Ltd.
• Autobahn Therapeutics, Inc.
• Navitor Pharmaceuticals, Inc.
• Takeda
• Syndeio Biosciences, Inc
• Suven Life Sciences Limited
• Definium Therapeutics US, Inc.
• Boehringer Ingelheim
• Relmada Therapeutics, Inc.
• Sirtsei Pharmaceuticals, Inc.
• Intra-Cellular Therapies, Inc.
• COMPASS Pathways
• Beijing Greatway Pharmaceutical Technology Co.,Ltd.
• Bausch Health Americas, Inc.
• Alto Neuroscience
• Gilgamesh Pharmaceuticals
• BioLite, Inc.
• Luye Pharma Group Ltd.
• Vigonvita Life Sciences
• Draig Therapeutics Ltd
• Supernus Pharmaceuticals, Inc.
• Ono Pharmaceutical Co. Ltd
• CSPC Ouyi Pharmaceutical Co., Ltd.
• Zhejiang Huahai Pharmaceutical Co., Ltd.
• Chengdu Kanghong Pharmaceutical Group Co., Ltd.
• Vanda Pharmaceuticals
• Seaport Therapeutics
• Jiangsu Nhwa Pharmaceutical Co., Ltd.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Sichuan Purity Pharmaceutical Technology Co., Ltd.
• ACADIA Pharmaceuticals Inc.
• Corium Innovations, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)